National Pharmacy Health & Leadership Alliance Verify a MemberMember Login
NPHLANational Pharmacy Health & Leadership Alliance
Apply for Membership

01MetabolicWhat Changed TodayUpdated

What changed today in Metabolic: 6 trial updates

Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.

By NPHLA IntelligencePublished Last updated Automated from official records

The signal

NPHLA tracked 6 new official records on this desk today: 6 trial updates.

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

What changed

  1. New trial registered: JOULE3 (Mechanisms of Weight Loss: Tirzepatide vs Semaglutide)[1]
  2. Results posted on ClinicalTrials.gov: GUARD (Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus)[2]
  3. Results posted on ClinicalTrials.gov: A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics[3]
  4. New trial registered: A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China[4]
  5. New trial registered: GLP-BARI-VAN (Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity)[5]
  6. New trial registered: SHAPe (Sustaining Health After an Intensive Weight-loss Pro-gramme)[6]
  7. Also reported by STAT: “STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study”.[7]
  8. Also reported by Endpoints News: “Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes”.[8]
  9. Also reported by BioPharma Dive: “Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial”.[9]

Who this affects

  • Weight-management clinics
  • Med spas
  • Pharmacists
  • Prescribers
  • Medical directors
  • Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

NPHLA takeaway

These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.

Source file

  1. [1]
    New trial registered: JOULE3 (Mechanisms of Weight Loss: Tirzepatide vs Semaglutide)

    Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)

  2. [2]
  3. [3]
  4. [4]
  5. [5]
  6. [6]
  7. [7]
    STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

    News reportingSTATIndustry coverage — headline and link only

  8. [8]
    Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes

    News reportingEndpoints NewsIndustry coverage — headline and link only

  9. [9]
    Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

    News reportingBioPharma DiveIndustry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.

Update timeline

  1. First published.
  2. Added 2 new official records.